Clinical Manufacture

Commercial Manufacture

Drug Product Fill & Finish

Development

Testing

Discovery

Antibody Drug Conjugates

Technologies & Platforms
Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologics in EU Clinical Trial
Mar 02, 2016

Highlights

First-Ever Chinese-Manufactured Biologic Dosed in a European Clinical Trial
Prima BioMedDosedFirst Patient in AIPAC Immuno-Oncology Trial in Metastatic Breast Cancer

SHANGHAI and SYDNEY, March 2, 2016 /PRNewswire/ — WuXi Biologics Co. Ltd., a wholly owned subsidiary of WuXi AppTec Co. Ltd. (WuXi),and Prima BioMed Ltd. (Prima) (ASX: PRR; NASDAQ: PBMD), a leading immuno-oncology company, announced today that through theirstrategic supply partnership, Prima’s first-in-class immuno-oncology product candidate IMP321 (LAG-3 Ig fusion protein), manufactured at WuXi’s state-of-the-art cGMP facility in China, has now been dosed in a Phase IIb clinical trial in Belgium.

This event represents two significant milestones. It is the first time a biologic manufactured in China has beenreleased for use in a clinical trial within countries in the EU. It alsomarksthe first patient being dosed in AIPAC(Active Immunotherapy PAClitaxel), Prima’s Phase IIb clinical trial in metastatic breast cancer.WuXi is supplying IMP321 to Prima’s AIPAC trial, which is being conducted in Europe,as well as to its TACTI-Mel Phase I melanoma trial currently recruiting in Australia.

Belgium’s Federal Agency for Medicines and Health Products approved the Clinical Trial Application (CTA) for IMP321 on October 25, 2015. The CTA was also approved in the Netherlands and is pending in several other EU countries.

“We are very pleased to work with such a distinguished team at Prima BioMed,” said Dr. Chris Chen, CEO of WuXi Biologics. “With the start of this exciting clinical trial for IMP321, in addition to recent CTA filings and approvals for other product candidates of WuXi partners, WuXi Biologics is rapidly becoming a significant contributor to the expedited development of innovative biologics in the EU.”

“We congratulate our partner Prima BioMed on their exciting progress,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “This milestone shows that WuXi’s strong investment in an integrated discovery, development and manufacturing platform in biologics continues to enable entrepreneurs around the world to realize their dreams of bringing potentially life-saving medicines to patients faster.”

Mr. Marc Voigt, CEO of Prima BioMed, added, “We have benefited greatly from the considerable expertise of the scientists and staff at WuXiin producing the material we need for our AIPAC clinical trial. The quality of the product WuXi produced and their high operating standards have been most impressive, and we are honored to be the first company to conduct a clinical trial in Europe with material produced in China.”

BACK